Patients with brain cancer have expressed disappointment after a drug that slows – or even stops – tumours growing was rejected for use on the NHS.
The National Institute for Health and Care Excellence (Nice) has published draft guidance turning down vorasidenib over uncertainties in the economic data and lack of clarity on whether the drug improves overall survival.
-copy-29e15046.jpeg?w=600)
